Overview

Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD

Status:
Recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of REL-1017 in patients with major depressive disorder (MDD).

Phase:

Phase 3

Details

Lead Sponsor:

Relmada Therapeutics, Inc.